FDA 483 - B. Braun Medical Inc - July 23, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of B. Braun Medical Inc. in Irvine, CA, a sterile drug manufacturer, revealed significant deficiencies in its quality control unit. The firm has multiple long-standing corrective and preventive actions (CAPAs) that remain incomplete, some dating back to a 2017 Warning Letter and a 2018 FDA-483. Additionally, investigations into out-of-specification (OOS) sterility test results were found to be inadequate, lacking proper follow-up and retraining, and critical equipment surfaces were observed to be worn, potentially compromising drug product quality.
ID · 7a9223d9-42ec-4229-9715-32858f2788e6